Skip to main content
NCBI home page
Cytotechnology logoLink to Cytotechnology
. 2003 Mar;41(2-3):197–206. doi: 10.1023/A:1024839225920

Nonmyeloablative stem cell transplantation as immunotherapy for kidney cancer and other metastatic solid tumors

Cristian Carvallo 1, Richard Childs 1,✉
PMCID: PMC3466686  PMID: 19002956

Abstract

Over the past few decades, great strides have been made to advance the field of allogeneic hematopoietic stem cell transplantation. The donor immune mediated graft-vs-tumor effect that follows the procedure is now widely accepted as the most effective form cancer immunotherapy available for patients with a variety of advanced hematological malignancies. Recognition that a transplanted immune system could cure patients with treatment refractory leukemia led to the development of `low-intensity' conditioning regimens, which have improved the safety of the procedure and broadened the application of allogeneic immunotherapy to a growing list of neoplastic diseases. Here we discuss the investigational use of allogeneic transplantation as immunotherapy for patients with metastatic, treatment-refractory solid tumors.

Keywords: allogeneic transplant, immunotherapy, graft-versus tumor, Nonmyeloablative stem cell transplant, Renal Cell Carcinoma.

Full Text

The Full Text of this article is available as a PDF (203.0 KB).

References

  1. Anderson LD, Jr, Mori S, Mann S, Savary CA. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease. Cancer Res. 2000;60:5797–5802. [PubMed] [Google Scholar]
  2. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature. 2001;411:385–389. doi: 10.1038/35077251. [DOI] [PubMed] [Google Scholar]
  3. Asai O, Longo DL, Tian Z, Hornung RL, Taub DD, Ruscetti FW, Murphy WJ. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effect by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest. 1998;101:1835–1842. doi: 10.1172/JCI1268. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Barnes DWH, Corp MJ, Loutit JF, Neal FE. Treatment of murine leukaemia with X-Rays and homologous bone marrow: Preliminary communication. Br Med J. 1956;2:626–627. doi: 10.1136/bmj.2.4993.626. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Barrett AJ. Mechanisms of Graft-versus-Leukemia Reaction. Stem Cell. 1997;15:248–258. doi: 10.1002/stem.150248. [DOI] [PubMed] [Google Scholar]
  6. Beguin Y, Collignon J, Laurent C, Fillet G. Spontaneous complete remission and recovery of donor haemopoiesis without GVHD after relapse and apparent marrow graft rejection in poorprognosis myelodysplastic syndrome. Br J Haematol. 1996;94:507–509. doi: 10.1046/j.1365-2141.1996.d01-1824.x. [DOI] [PubMed] [Google Scholar]
  7. Ben-Yosef R, Or R, Nagler A, Slavin S. Graft-versustumour and graft-versus-leukaemia effect in patient with concurrent breast cancer and acute myelocytic leukaemia. Lancet. 1996;348:1242–1243. doi: 10.1016/S0140-6736(05)65517-1. [DOI] [PubMed] [Google Scholar]
  8. Baron F, Beguin Y. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic HPC transplantation. Transfusion. 2000;40:468–476. doi: 10.1046/j.1537-2995.2000.40040468.x. [DOI] [PubMed] [Google Scholar]
  9. Bay JO, Choufi B, Pomel C, Dauplat J, Durando X, Tournilhac O, Travade P, Plagne R, Blaise D. Potential allogeneic graft-versus-tumor effect in a patient with ovarian cancer. Bone Marrow Transplant. 2000;25:681–682. doi: 10.1038/sj.bmt.1702206. [DOI] [PubMed] [Google Scholar]
  10. Bay JO, Fleury J, Choufi B, Tournilhac O, Vincent C, Bailly C, Dauplat J, Viens P, Faucher C, Blaise D. Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: Results of five patients. Bone Marrow Transplant. 2002;30:95–102. doi: 10.1038/sj.bmt.1703609. [DOI] [PubMed] [Google Scholar]
  11. Blaise DP, Bay JO, Michallet M, Boiron JM, Cahn JY, Ifrah N, Sotto JJ, Gratecos N, Faucher C, Blay JY, Olive D, Maraninchi D & Viens P (2002) A feasibility study of allogeneic immunotherapy for solid tumors. Proc A Soc Clin Oncol, A1664.
  12. Bornhauser M, Haenel M, Platzbecker U, Roellig C, Waessa T, Schmidt H, Ehninger G & Kroschinsky F (2002) Graft-versus-tumor effects after reduced intensity conditioning and allogeneic hematopoietic stem cell transplantation for ovarian cancer. Proc A Soc Clin Oncol: A2954.
  13. Bregni M, Dodero A, Peccatori J, Pescarollo A, Bernardi M, Sassi I, Voena C, Zaniboni A, Bordignon C, Corradini P. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood. 2002;99:4234–4236. doi: 10.1182/blood.V99.11.4234. [DOI] [PubMed] [Google Scholar]
  14. Bregni M, Peccatori J, Dodero A, Bernardi M, Corti C, Pescarollo A, Ciceri F, Bordignon C & Corradini P (2002) Clinical responses to reduced-intensity allogeneic stem cell transplantation in solid tumors: Strong association with graft-versus-host disease. Proc A Soc Clin Oncol, A1665.
  15. Champlin R, Khouri I, Shimoni A, et al. Harnessing graftversus malignancy: Non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol. 2000;111:18–29. doi: 10.1046/j.1365-2141.2000.02196.x. [DOI] [PubMed] [Google Scholar]
  16. Childs R, Clave E, Contentin N, Jayasekera D, Hensel N, Leitman S, Read EJ, Carter C, Bahceci E, Young NS, Barrett AJ. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses. Blood. 1999;94:3234–3241. [PubMed] [Google Scholar]
  17. Childs R, Bradstock KF, Gottlieb D, et al. Nonmyeloablative stem cell transplantation as immunotherapy for metastatic melanoma: Results of a pilot study. Blood. 2000;96:A3536. [Google Scholar]
  18. Childs R, Chernoff A, Contenin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000;343:750–758. doi: 10.1056/NEJM200009143431101. [DOI] [PubMed] [Google Scholar]
  19. Eibl B, Schwaighofer H, Nachbaur D, Marth C, Gächter A, Knapp R, Böck G, Gassner C, Schiller L, Petersen F, Niederweiser D. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood. 1996;88:1501–1508. [PubMed] [Google Scholar]
  20. Fefer A, Sullivan KM, Weiden P, et al. Graft versus leukemia effect in man: The relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation. In: Truitt RL, Gale RP, Bortin MM, et al., editors. Cellular Immunotherapy of Cancer. New York: Alan R Liss; 1987. pp. 401–408. [PubMed] [Google Scholar]
  21. Gale RP, Horwitz MM. Graft-versus-leukemia in bone marrow transplantation. The Advisory Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplant Registry. Bone Marrow Transplant. 1990;6(1):94–97. [PubMed] [Google Scholar]
  22. Gambacorti-Passerini C, Bertazzoli C, Dermime S, Scardino A, Schendel D, Parmiani G. Mapping of HLA class I bindings motifs in forty-four fusion proteins involved in human cancers. Clin Cancer Res. 1997;3:675–683. [PubMed] [Google Scholar]
  23. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippoliti C, Claxton DF, Donato M, Bruton J, Cohen A, Davis M, Andersson B, Anderlini P, Gajewski J, Kornblau S, Andreef M, Przepiorka D, Ueno NT, Molldrem J, Champlin R. Melphalan and purine analog-containing preparative regimens: Reducedintensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001;97:631–637. doi: 10.1182/blood.V97.3.631. [DOI] [PubMed] [Google Scholar]
  24. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin R, Gluckman E, Hoffman M, Jacobsen N, Marmont AM, McGlave P. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk of relapse associated with T-cell depletion. Ann Intern Med. 1988;108:806–811. doi: 10.7326/0003-4819-108-6-806. [DOI] [PubMed] [Google Scholar]
  25. Goulmy E. Human minor histocompatibility antigens: New concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev. 1997;157:125–140. doi: 10.1111/j.1600-065X.1997.tb00978.x. [DOI] [PubMed] [Google Scholar]
  26. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versusleukemia reactions after bone marrow transplantation. Blood. 1990;75:555–562. [PubMed] [Google Scholar]
  27. Jiang YZ, Cullis JO, Kanfer EJ, Goldman JM, Barrett AJ. T cell and NK cell mediated graft versus leukemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant. 1993;11:133–138. [PubMed] [Google Scholar]
  28. Junghanss C, Marr K, Carter R, Sandmeier B, Maris M, Maloney D, Chauncey T, McSweeney P, Storb R. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: A matched control study. Biol of Blood and Marrow Trans. 2002;8:512–520. doi: 10.1053/bbmt.2002.v8.pm12374456. [DOI] [PubMed] [Google Scholar]
  29. Kolb HJ, Mittermuller J, Clemm C, Lederose G, Brehm G, Heim M, Wilmanns W. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76:2462–2465. [PubMed] [Google Scholar]
  30. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederweiser D. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European group for blood and marrow transplantation working party chronic leukemia. Blood. 1995;86:2041–2050. [PubMed] [Google Scholar]
  31. Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, Peggs K, Verfuerth S, Pettengell R, Marsh JC, Schey S, Mahendra P, Morgan GJ, Hale G, Waldmann H, de Elvira MC, Williams CD, Devereux S, Linch DC, Goldstone AH, Mackinnon S. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 2000;96:2419–2425. [PubMed] [Google Scholar]
  32. Lamb LS, Jr, Henslee-Downey PJ, Parrish RS, Godder K, Thompson J, Lee C, Gee AP. Increased frequency of TCR gamma delta + T cells in disease-free survivors following T cell-depleted, partially mismatched, related donor bone marrow transplantation for leukemia. J Hematother. 1996;5:503–509. doi: 10.1089/scd.1.1996.5.503. [DOI] [PubMed] [Google Scholar]
  33. Lee M, Champlin R, Kantarjian H, Stass S. Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukemia following allogeneic bone marrow transplantation. Br J Haematol. 1992;82:708–714. doi: 10.1111/j.1365-2141.1992.tb06948.x. [DOI] [PubMed] [Google Scholar]
  34. Mattei D, Saglio G, Gottardi E, Gallamini A, Mordini N, Bacigalupo A. Persisting molecular remission ten years after donor lymphocyte infusion for hematologic relapse in chronic myeloid leukemia. Haematologica. 2001;86:545–546. [PubMed] [Google Scholar]
  35. McSweeney PA, Niederweiser D, Shizuru J, Sandmaier BM, Molina A, Maloney DG, Chauncey TR, Gooley T, Hegenbart U, Nash RA, Radich J, Wagner JL, Minor S, Appelbaum FR, Bensinger WI, Bryan E, Flowers ED, Georges G, Grumet FC, Kiem HP, Torok-Storb B, Yu C, Blume KG, Storb R. Hematopoietic cell transplantation in older patients with hematological malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97:3390–3400. doi: 10.1182/blood.V97.11.3390. [DOI] [PubMed] [Google Scholar]
  36. Mehta J, Powles R, Kulkarni S, Treleaven J, Singhal S. Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: Single-center experience of 32 adult patients. Bone Marrow Transplant. 1997;20:129–135. doi: 10.1038/sj.bmt.1700859. [DOI] [PubMed] [Google Scholar]
  37. Melioli G, Guastella M, Semino C, Meta M, Pietra G, Ponte M, Queirolo P, Sertoli MR, Martini L, Reali UM. Proliferative, phenotypic and functional and molecular characteristics of tumor-infiltrating lymphocytes obtained from unselected patients with malignant melanomas and expanded in vitro in the presence of recombinant interleukin-2. Melanoma Res. 1994;4:127–133. doi: 10.1097/00008390-199404000-00007. [DOI] [PubMed] [Google Scholar]
  38. Morecki S, Gelfand Y, Levi S, Nagler A, Condiotti R, Nabet C, Ackerstein A, Slavin S. Activated long-term peripheral blood cultures as preparation for adoptive alloreactive therapy in cancer patients. J Hematother. 1997;6:115–124. doi: 10.1089/scd.1.1997.6.115. [DOI] [PubMed] [Google Scholar]
  39. Morecki S, Slavin S. Toward amplification of a graft-versus-leukemia effect While minimizing graft-versus-host disease. J Hematother Stem Cell Res. 2000;9:355–366. doi: 10.1089/15258160050079461. [DOI] [PubMed] [Google Scholar]
  40. Moscardo F, Martinez JA, Sanz G, Jimenez C, Cervera J, Sanchis J, Vera FJ, Sanz MA. Graft-versus-tumour effect in non-small-cell lung cancer after peripheral blood stem cell transplantation. Br J of Haemat. 2000;111:708–710. doi: 10.1046/j.1365-2141.2000.02368.x. [DOI] [PubMed] [Google Scholar]
  41. Moscovitch M, Slavin S. Antitumor effects of allogeneic bone marrow transplantation in (NZB X NZW) F1 hybrids with spontaneous lymphosarcoma. J Immunol. 1984;132:997–1003. [PubMed] [Google Scholar]
  42. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol. 2000;163:408–417. doi: 10.1016/S0022-5347(05)67889-5. [DOI] [PubMed] [Google Scholar]
  43. Ohminami H, Yasukawa M, Fujita S. HLA class-I restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT-1 peptide. Blood. 2000;95:286–293. [PubMed] [Google Scholar]
  44. Oka Y, Elisseeva OA, Tsuboi A, Ogawa H, Tamaki H, Li H, Oji Y, Kim EH, Soma T, Asada M, Ueda K, Maruya E, Saji H, Kishimoto T, Udaka K, Sugiyama H. Human cytotoxic T-lymphocyte responses specific for peptides of the wildtype Wilms' tumor gene (WT-1) product. Immunogenetics. 2000;51:99–107. doi: 10.1007/s002510050018. [DOI] [PubMed] [Google Scholar]
  45. Pedrazzoli P, Giorgiani G, Schiavo R, Renga M, Sironi O, Locatelli F & Siena S (2002a) Allogeneic hematopoietic stem cell transplantation (alloHSCT) following reduced-intensity chemotherapy for sarcoma. Proc A Soc Clin Oncol: A2949.
  46. Pedrazzolli P, Da Prada GA, Giorgiani G, Schiavo R, Zambelli A, Giraldi E, Landonio G, Locatelli F, Siena S, Della Cuna GR. Allogeneic blood stem transplantation after a reducedintensity, preparative regimen. Cancer. 2002;94:2409–2415. doi: 10.1002/cncr.10491. [DOI] [PubMed] [Google Scholar]
  47. Rini B, Zimmerman T, Galewski T, Stadler W, Vogelsang N. Allogeneic peripheral blood stem transplantation for metastatic renal cell carcinoma. J of Urol. 2001;165:1208–1209. doi: 10.1097/00005392-200104000-00040. [DOI] [PubMed] [Google Scholar]
  48. Rini B, Zimmerman T, Stadler W, Gajewski T, Vogelzang J. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: Feasibility, engraftment, and clinical results. J Clin Oncol. 2002;20:2017–2024. doi: 10.1200/JCO.2002.08.068. [DOI] [PubMed] [Google Scholar]
  49. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE. Treatment of 283 consecutive patients with metastatic melanoma or renal cell carcinoma using high-dose bolus interleukin-2. JAMA. 1994;271:903–913. [PubMed] [Google Scholar]
  50. Ruggeri L, Capanni M, Casucci M, Volpi I, Toski A, Perruccio K, Urbani E, Negrin RS, Martelli MF, Velardi A. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 1999;94:333–339. [PubMed] [Google Scholar]
  51. Ruggeri L, Capanni M, Urbani E, Perruccio K, Schlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097–2100. doi: 10.1126/science.1068440. [DOI] [PubMed] [Google Scholar]
  52. Sandmaier B, Masood N, Thompson J & Storb R (2002) Fludarabine and total body irradiation (TBI), followed by allogeneic hematopoietic stem cell transplant (HSCT) as immunotherapy for metastatic renal cell carcinoma (MRCC) Proc A Soc Clin Oncol, A1677.
  53. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756–763. [PubMed] [Google Scholar]
  54. Slavin S, Or R, Prighozina T, Gurevich O, Aker M, Panighari S, Shapira M, Nagler A. Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man. Bone Marrow Transplantation. 2000;25(2):S54–S57. doi: 10.1038/sj.bmt.1702356. [DOI] [PubMed] [Google Scholar]
  55. Spitzer TR, McAfee S, Sackstein R, et al. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant. 2000;6:309–320. doi: 10.1016/S1083-8791(00)70056-5. [DOI] [PubMed] [Google Scholar]
  56. Sullivan KM, Weiden PL, Storb R, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood. 1989;73:1720–1728. [PubMed] [Google Scholar]
  57. Sullivan KM, Storb R, Buckner CD, et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med. 1989;320:828–834. doi: 10.1056/NEJM198903303201303. [DOI] [PubMed] [Google Scholar]
  58. Suzuki R, Taji H, Iida S, Miura K, Kagami Y, Ogura M, Yatabe Y, Nakamura S, Seto M, Morishima Y. Complete cytogenetic response with host-derived hematopoiesis induced by cyclosporin A discontinuation in a patient with relapsed chronic myelogenous leukemia after bone marrow transplantation. Bone Marrow Transplant. 1997;20:615–617. doi: 10.1038/sj.bmt.1700929. [DOI] [PubMed] [Google Scholar]
  59. Teshima T, Liu C, Lowler K, Dranoff G, Ferrara JLM. Donor leukocyte infusion from immunized donors increases tumor vaccine efficacy after allogeneic bone marrow transplantation. Cancer Res. 2002;62:796–800. [PubMed] [Google Scholar]
  60. Thomas ED, Storb R, Clift RA, et al. Bone-marrow transplantation. N Engl J Med. 1975;292:832–843. doi: 10.1056/NEJM197504172921605. [DOI] [PubMed] [Google Scholar]
  61. Truitt RL, Atasoylu AA. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transplant. 1991;8:51–58. [PubMed] [Google Scholar]
  62. Ueno N, Rondon G, Mirza NQ, Geisler DK, Anderlini P, Giralt S, Andersson BS, Claxton DF, Gajewski JL, Khouri IF, Körbling M, Mehra RC, Przepiorka D, Rahman Z, Samuels BI, Van Besien K, Hortobagyi GN, Champlin RE. Allogeneic peripheralblood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol. 1998;16:986–993. doi: 10.1200/JCO.1998.16.3.986. [DOI] [PubMed] [Google Scholar]
  63. Warren EH, Greenberg PD, Riddell SR. Cytotoxic Tlymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood. 1998;91:2197–2207. [PubMed] [Google Scholar]
  64. Warren EH, Gavin M, Greenberg PD, Riddell SR. Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation. Curr Opin Hematol. 1998;5:429–433. doi: 10.1097/00062752-199811000-00013. [DOI] [PubMed] [Google Scholar]
  65. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300:1068–1073. doi: 10.1056/NEJM197905103001902. [DOI] [PubMed] [Google Scholar]
  66. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED, the Seattle Marrow Transplant Team Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med. 1981;304:1529–1533. doi: 10.1056/NEJM198106183042507. [DOI] [PubMed] [Google Scholar]
  67. Yannelli JR, Hyatt C, McConnell S, Hines K, Jacknin L, Parker L, Sanders M, Rosenberg SA. Growth of tumor-infiltrating lymphocytes from human solid cancers: Summary of a 5-year experience. Int J Cancer. 1996;65:413–421. doi: 10.1002/(SICI)1097-0215(19960208)65:4<413::AID-IJC3>3.0.CO;2-#. [DOI] [PubMed] [Google Scholar]

Articles from Cytotechnology are provided here courtesy of Springer Science+Business Media B.V.

RESOURCES